Charities lobby EU over access to generic drugs.
London. BMJ (online)
(Impact Factor: 17.45).
02/2012; 344:e1066. DOI: 10.1136/bmj.e1066
Available from: Thomas Dorlo
Indian Journal of Medical Ethics 05/2013; 10(2):118-120. · 1.07 Impact Factor
BMJ (online) 02/2012; 344(feb21 1):e1279. DOI:10.1136/bmj.e1279 · 17.45 Impact Factor
Available from: Ellen 't Hoen
[Show abstract] [Hide abstract]
ABSTRACT: Purpose of review:
The purpose of this study is to review relevant literature published from January 2011 to July 2012 that specifically addresses the impact of intellectual property protection on access to antiretroviral drugs.
The articles reviewed discussed the relation of intellectual property protection and access to medicines. For most authors, the World Trade Organization (WTO) Trade-Related Intellectual Property Rights Agreement (TRIPS) and the 10-year anniversary of the 2001 WTO Doha Declaration on TRIPS and Public Health formed an important background for the review of the current state of play.
Intellectual property plays an important role in implementing policies to ensure HIV treatment and care programmes. From the review, three main themes emerged: the implementation of the Doha Declaration, the role of generic competition in antiretroviral treatment scale-up and innovative licensing mechanisms. The attention for the effects of intellectual property on access to HIV medicines opened the path for new initiatives for the management of patents using public health objectives as the key driver such as the UNITAID-backed Medicines Patent Pool. Some of the literature addressed the question whether more fundamental changes in the intellectual property architecture were necessary.
Current opinion in HIV and AIDS 11/2012; 8(1). DOI:10.1097/COH.0b013e32835b6e5a · 4.68 Impact Factor
Data provided are for informational purposes only. Although carefully collected, accuracy cannot be guaranteed. The impact factor represents a rough estimation of the journal's impact factor and does not reflect the actual current impact factor. Publisher conditions are provided by RoMEO. Differing provisions from the publisher's actual policy or licence agreement may be applicable.